Keytruda's Approvals Across Cancer Types
Keytruda (pembrolizumab), a PD-1 inhibitor from Merck, is FDA-approved for over 20 cancer indications beyond its original melanoma use. It works by blocking the PD-1 protein on T-cells, unleashing immune attacks on tumors expressing PD-L1. Effectiveness varies by cancer type, PD-L1 status, tumor mutation burden, and combination with chemo or other drugs. Real-world data shows response rates from 10-60%, with durable responses in responders.[1][2]
How It Performs in Lung Cancer
Keytruda leads non-small cell lung cancer (NSCLC) treatment, especially PD-L1-positive cases. KEYNOTE-024 trial showed 45% objective response rate (ORR) and 30% five-year survival vs. 16% with chemo alone in first-line high-PD-L1 NSCLC. In broader KEYNOTE-189/407 studies with chemo, it cut mortality risk by 51% and 38%, respectively. Approved for small cell lung cancer too, with 18-21% ORR in combos.[3][4]
Results in Head and Neck, Bladder, and MSI-High Cancers
In recurrent/metastatic head and neck squamous cell carcinoma, KEYNOTE-048 gave median survival of 13 months vs. 10 with chemo. Urothelial (bladder) cancer sees 20-30% ORR in PD-L1-high second-line cases, rising to 40% with Enfortumab vedotin. For microsatellite instability-high (MSI-H) tumors—regardless of origin like colorectal or endometrial—ORR hits 40-50%, with FDA tissue-agnostic approval.[5][6]
Effectiveness in Triple-Negative Breast Cancer and Others
Combined with chemo, Keytruda boosts early-stage triple-negative breast cancer (TNBC) pathologic complete response to 65% (KEYNOTE-522), improving event-free survival by 37%. In Hodgkin lymphoma, ORR exceeds 70% post-multiple lines. Approvals extend to cervical, gastric, hepatocellular, Merkel cell, renal cell, and endometrial cancers, with ORR 15-50% depending on line and combo.[7][8]
What Limits Effectiveness and Resistance Factors
Not all patients respond; PD-L1-negative tumors have lower rates (10-20%). Primary resistance affects 60-80%, secondary in 20-30% of responders due to tumor evolution or low T-cell infiltration. Biomarkers like tumor mutational burden help predict success. Ongoing trials test combos with TIGIT inhibitors or vaccines to overcome this.[9]
Survival Benchmarks by Cancer Type
| Cancer Type | Key Trial | Median PFS (months) | Median OS (months) | 5-Year OS Rate |
|-------------|-----------|---------------------|--------------------|---------------|
| NSCLC (PD-L1 ≥50%) | KEYNOTE-024 | 10.3 vs. 6.0 | NR vs. 14.2 | 31.9% vs. 16.3% |
| Melanoma | KEYNOTE-006 | 5.6 vs. 2.8 | 32.7 vs. 15.9 | ~34% |
| MSI-H/dMMR | KEYNOTE-177 | 16.5 vs. 8.2 | NR vs. 21.9 | N/A |
| TNBC (neoadjuvant) | KEYNOTE-522 | N/A | Event-free: 84% vs. 77% at 3 yrs | N/A[10] |
Upcoming Expansions and Biosimilar Threats
Keytruda's label grows with trials in prostate, ovarian, and pancreatic cancers, though single-agent ORR stays low (5-15%). Patent expiry starts 2028 for composition-of-matter, with challenges from Amgen and others; biosimilars could enter post-2030 if litigation fails. DrugPatentWatch tracks 50+ patents, some extending to 2036.[11][12]
Sources
[1]: FDA.gov - Keytruda Label (updated 2024) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer
[2]: Merck.com - Keytruda Mechanism https://www.merck.com/product/usa/picirculars/k/keytruda/keytrudapi.pdf
[3]: NEJM - KEYNOTE-024 (2016) https://www.nejm.org/doi/full/10.1056/NEJMoa1606774
[4]: Lancet - KEYNOTE-189 (2018) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext
[5]: NEJM - KEYNOTE-048 (2019) https://www.nejm.org/doi/full/10.1056/NEJMoa1811801
[6]: FDA.gov - MSI-H Approval (2017) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-adult-refractory-msi-h-solid-tumors
[7]: NEJM - KEYNOTE-522 (2020) https://www.nejm.org/doi/full/10.1056/NEJMoa1910549
[8]: ASCO Post - Hodgkin Data https://ascopost.com/issues/may-25-2017/keytruda-shows-69-or-r-in-relapsed-refractory-hodgkin-lymphoma/
[9]: Nature Reviews Cancer - Resistance (2022) https://www.nature.com/articles/s41568-022-00472-7
[10]: PolyData from Keytruda Trials (Merck 2023 Investor Report) https://www.merck.com/investor-relations/
[11]: ClinicalTrials.gov - Ongoing Studies https://clinicaltrials.gov/search?term=pembrolizumab
[12]: DrugPatentWatch.com - Keytruda Patents https://www.drugpatentwatch.com/p/tradename/KEYTRUDA